SRPK1 and prostate cancer: This has been established through use of SRPK1 inhibiting compounds SRPN340 and Sphinx31 in a variety of tissues, including the kidney (Amin et al., 2011), retinal epithelium (Gammons et al., 2013; Batson et al., 2017), peripheral neurones (Hulse et al., 2014), prostate cancer (Mavrou and Oltean, 2016), and acute myeloid leukaemia (Tzelepis et al., 2018).